Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Neoplasms | 7 | 2026 | 453 | 1.810 |
Why?
|
| Sarcoma | 5 | 2026 | 212 | 1.500 |
Why?
|
| Osteosarcoma | 6 | 2026 | 268 | 1.330 |
Why?
|
| Rhabdomyosarcoma | 5 | 2026 | 228 | 1.240 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2023 | 52 | 0.920 |
Why?
|
| Mitotane | 1 | 2024 | 2 | 0.860 |
Why?
|
| Sarcoma, Ewing | 5 | 2026 | 117 | 0.850 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2024 | 11 | 0.850 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2024 | 24 | 0.840 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2023 | 41 | 0.770 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2024 | 256 | 0.750 |
Why?
|
| Hemangioendothelioma | 1 | 2022 | 25 | 0.720 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2022 | 15 | 0.720 |
Why?
|
| Wilms Tumor | 2 | 2026 | 120 | 0.720 |
Why?
|
| Kidney Neoplasms | 3 | 2026 | 454 | 0.690 |
Why?
|
| MicroRNAs | 3 | 2018 | 901 | 0.690 |
Why?
|
| Sarcoma, Kaposi | 1 | 2022 | 130 | 0.650 |
Why?
|
| Neoplasms | 7 | 2026 | 2968 | 0.610 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2018 | 11 | 0.540 |
Why?
|
| Biomarkers, Tumor | 4 | 2026 | 1624 | 0.520 |
Why?
|
| Retinal Neoplasms | 1 | 2018 | 74 | 0.510 |
Why?
|
| Exanthema | 1 | 2017 | 74 | 0.480 |
Why?
|
| Hepatoblastoma | 1 | 2018 | 199 | 0.450 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 1552 | 0.430 |
Why?
|
| Adolescent | 21 | 2026 | 21021 | 0.420 |
Why?
|
| Skin | 1 | 2017 | 553 | 0.420 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1851 | 0.400 |
Why?
|
| Patient Participation | 3 | 2026 | 246 | 0.380 |
Why?
|
| Oncologists | 2 | 2023 | 32 | 0.360 |
Why?
|
| Decision Making | 3 | 2026 | 693 | 0.340 |
Why?
|
| Young Adult | 11 | 2026 | 10131 | 0.330 |
Why?
|
| Liver Neoplasms | 2 | 2018 | 1408 | 0.320 |
Why?
|
| Humans | 34 | 2026 | 132194 | 0.280 |
Why?
|
| Transcriptome | 1 | 2015 | 1141 | 0.270 |
Why?
|
| Parents | 2 | 2026 | 1123 | 0.260 |
Why?
|
| Child | 16 | 2025 | 26383 | 0.240 |
Why?
|
| Cyclophosphamide | 3 | 2023 | 440 | 0.230 |
Why?
|
| Ribonuclease III | 1 | 2026 | 103 | 0.230 |
Why?
|
| Appendiceal Neoplasms | 1 | 2025 | 22 | 0.230 |
Why?
|
| Colectomy | 1 | 2025 | 89 | 0.220 |
Why?
|
| Appendectomy | 1 | 2025 | 88 | 0.220 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2026 | 162 | 0.220 |
Why?
|
| Neuroendocrine Tumors | 1 | 2025 | 70 | 0.220 |
Why?
|
| Trophoblastic Tumor, Placental Site | 1 | 2024 | 1 | 0.210 |
Why?
|
| Patient Preference | 1 | 2026 | 147 | 0.210 |
Why?
|
| Bronchial Neoplasms | 1 | 2024 | 16 | 0.210 |
Why?
|
| Trophoblastic Neoplasms | 1 | 2024 | 5 | 0.210 |
Why?
|
| Gestational Trophoblastic Disease | 1 | 2024 | 10 | 0.210 |
Why?
|
| Carcinoid Tumor | 1 | 2024 | 24 | 0.210 |
Why?
|
| Female | 18 | 2026 | 71459 | 0.200 |
Why?
|
| Chilblains | 1 | 2023 | 3 | 0.200 |
Why?
|
| Leuprolide | 1 | 2023 | 23 | 0.200 |
Why?
|
| Ovarian Reserve | 1 | 2023 | 12 | 0.200 |
Why?
|
| Lymph Nodes | 1 | 2025 | 364 | 0.190 |
Why?
|
| Uterine Neoplasms | 1 | 2024 | 107 | 0.190 |
Why?
|
| Pneumonectomy | 1 | 2024 | 151 | 0.190 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 101 | 0.180 |
Why?
|
| Molecular Biology | 1 | 2022 | 68 | 0.180 |
Why?
|
| Neoplasm Staging | 4 | 2025 | 1333 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2023 | 239 | 0.170 |
Why?
|
| Hormone Replacement Therapy | 1 | 2024 | 215 | 0.170 |
Why?
|
| Physicians, Women | 1 | 2021 | 50 | 0.170 |
Why?
|
| Doxorubicin | 3 | 2023 | 301 | 0.170 |
Why?
|
| Legislation, Drug | 1 | 2020 | 8 | 0.170 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 27 | 0.170 |
Why?
|
| Proton Therapy | 1 | 2022 | 158 | 0.170 |
Why?
|
| Pulmonary Artery | 1 | 2024 | 443 | 0.160 |
Why?
|
| Career Choice | 1 | 2021 | 164 | 0.160 |
Why?
|
| Adult | 9 | 2026 | 31771 | 0.160 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 81 | 0.160 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 129 | 0.160 |
Why?
|
| Male | 14 | 2026 | 65494 | 0.150 |
Why?
|
| Fertility Preservation | 1 | 2020 | 62 | 0.150 |
Why?
|
| Prognosis | 3 | 2018 | 4965 | 0.140 |
Why?
|
| Chronic Disease | 1 | 2023 | 1240 | 0.140 |
Why?
|
| Genomics | 3 | 2024 | 1633 | 0.140 |
Why?
|
| Endothelial Cells | 1 | 2022 | 530 | 0.140 |
Why?
|
| Epigenomics | 1 | 2019 | 182 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2020 | 268 | 0.140 |
Why?
|
| Blueberry Plants | 1 | 2017 | 6 | 0.130 |
Why?
|
| GTPase-Activating Proteins | 1 | 2017 | 86 | 0.130 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1140 | 0.120 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1282 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2021 | 721 | 0.120 |
Why?
|
| Sarcoma, Experimental | 1 | 2015 | 15 | 0.120 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 534 | 0.120 |
Why?
|
| Child, Preschool | 5 | 2025 | 15103 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2019 | 738 | 0.110 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2015 | 165 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2015 | 195 | 0.100 |
Why?
|
| Allografts | 1 | 2015 | 216 | 0.100 |
Why?
|
| Surveys and Questionnaires | 4 | 2026 | 4078 | 0.100 |
Why?
|
| ROC Curve | 1 | 2015 | 625 | 0.100 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 232 | 0.090 |
Why?
|
| Vincristine | 2 | 2023 | 194 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2026 | 5284 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1916 | 0.090 |
Why?
|
| Infant | 4 | 2026 | 13356 | 0.090 |
Why?
|
| Neoplasm Metastasis | 3 | 2018 | 710 | 0.080 |
Why?
|
| Survival Rate | 3 | 2024 | 2154 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 2031 | 0.080 |
Why?
|
| Etoposide | 2 | 2023 | 117 | 0.070 |
Why?
|
| Retrospective Studies | 6 | 2025 | 17772 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2014 | 557 | 0.070 |
Why?
|
| Pediatrics | 1 | 2018 | 1243 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2995 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2015 | 3864 | 0.060 |
Why?
|
| United States | 4 | 2025 | 11867 | 0.060 |
Why?
|
| Margins of Excision | 1 | 2025 | 56 | 0.060 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2018 | 999 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4694 | 0.050 |
Why?
|
| Mice | 3 | 2017 | 18399 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8615 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2026 | 806 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 910 | 0.050 |
Why?
|
| Europe | 1 | 2025 | 373 | 0.050 |
Why?
|
| Lymphatic Metastasis | 1 | 2025 | 433 | 0.050 |
Why?
|
| Germ-Line Mutation | 1 | 2026 | 375 | 0.050 |
Why?
|
| Cysts | 1 | 2024 | 93 | 0.050 |
Why?
|
| Survivorship | 1 | 2023 | 46 | 0.050 |
Why?
|
| Erythema | 1 | 2023 | 29 | 0.050 |
Why?
|
| Aneurysm, False | 1 | 2024 | 85 | 0.050 |
Why?
|
| Anti-Mullerian Hormone | 1 | 2023 | 45 | 0.050 |
Why?
|
| Protons | 1 | 2022 | 100 | 0.050 |
Why?
|
| Radiotherapy Dosage | 1 | 2022 | 221 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3858 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 1351 | 0.040 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2022 | 106 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 60 | 0.040 |
Why?
|
| Counseling | 1 | 2023 | 238 | 0.040 |
Why?
|
| Ovary | 1 | 2024 | 363 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2024 | 1082 | 0.040 |
Why?
|
| Pregnancy | 2 | 2024 | 7604 | 0.040 |
Why?
|
| Government Regulation | 1 | 2020 | 44 | 0.040 |
Why?
|
| Survivors | 1 | 2023 | 352 | 0.040 |
Why?
|
| United States Food and Drug Administration | 1 | 2020 | 156 | 0.040 |
Why?
|
| Animals | 3 | 2017 | 34291 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2024 | 404 | 0.040 |
Why?
|
| Apoptosis | 2 | 2017 | 1863 | 0.040 |
Why?
|
| Placenta | 1 | 2024 | 526 | 0.040 |
Why?
|
| Mutation | 2 | 2026 | 6207 | 0.040 |
Why?
|
| Risk Factors | 2 | 2023 | 11041 | 0.030 |
Why?
|
| Fertility | 1 | 2020 | 266 | 0.030 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2017 | 32 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 916 | 0.030 |
Why?
|
| Feedback, Physiological | 1 | 2017 | 67 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2024 | 1107 | 0.030 |
Why?
|
| p21-Activated Kinases | 1 | 2017 | 56 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2017 | 112 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 302 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2017 | 580 | 0.030 |
Why?
|
| Phenotype | 1 | 2026 | 4550 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2130 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 986 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 259 | 0.030 |
Why?
|
| Caspase 2 | 1 | 2015 | 27 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 106 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 313 | 0.030 |
Why?
|
| Proteomics | 1 | 2019 | 612 | 0.030 |
Why?
|
| Consolidation Chemotherapy | 1 | 2014 | 7 | 0.030 |
Why?
|
| 3-Iodobenzylguanidine | 1 | 2014 | 12 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2015 | 227 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2026 | 3439 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 120 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2015 | 158 | 0.030 |
Why?
|
| Carboplatin | 1 | 2014 | 80 | 0.030 |
Why?
|
| Lung | 1 | 2022 | 1580 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2014 | 55 | 0.030 |
Why?
|
| Aged | 2 | 2023 | 21304 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2014 | 137 | 0.030 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 166 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2015 | 249 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 359 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 755 | 0.030 |
Why?
|
| Cell Movement | 1 | 2017 | 882 | 0.030 |
Why?
|
| Homozygote | 1 | 2015 | 550 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2015 | 831 | 0.020 |
Why?
|
| Quality of Life | 1 | 2023 | 2117 | 0.020 |
Why?
|
| Cisplatin | 1 | 2014 | 289 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 1009 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 2015 | 653 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2022 | 3721 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2015 | 938 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 2367 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2017 | 2488 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2023 | 13022 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4734 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2014 | 1270 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 4699 | 0.010 |
Why?
|
| Middle Aged | 1 | 2021 | 28963 | 0.010 |
Why?
|